Mycobacterium Citations List: March 2025

Literature Citations

1. 1,3,4-oxadiazoles with Effective Anti-mycobacterial Activity. Andriato, P.M., V.P. Baldin, A.L. de Almeida, E.G. Sampiron, S.S.N. de Vasconcelos, K.R. Caleffi-Fercioli, R.B.L. Scodro, J.E. Meneguello, B. Maigret, S. Kioshima É, and R.F. Cardoso. Letters in Applied Microbiology, 2025. 78(3). PMID[40036865].
[PubMed]. TB_03_2025.

2. In Vitro Activity of the Triazinyl Diazepine Compound FTSD2 against Drug-resistant Mycobacterium tuberculosis Strains. Aranaga, C., R. Varela, A. Falco, J. Villa, L.M. Moreno, M. Causse, and L. Martínez-Martínez. Pharmaceuticals, 2025. 18(3). PMID[40143137]. PMCID[PMC11945624].
[PubMed]. TB_03_2025.

3. 2-substituted and 1,2-disubstitued Benzimidazole Derivatives: Synthesis and Identification of Potential Antibacterial Agents. Arya, C.G., J. Kumari, J. Kishan, K. Goswami, D. Sriram, S.A. Salim, P. Pakhira, S. Busi, M. Alharbi, M. Chandrakanth, M. Pasupuleti, and J. Banothu. Journal of Molecular Structure, 2025. 1333: 141693. ISI[001430675800001].
[WOS]. TB_03_2025.

4. Antimycobacterial Activity of Luteolin in Resistant Mycobacterium tuberculosis Isolates and Cytotoxicity on L929 cells. Aydin, E., M.K. Gunduz, G. Kaymak, A.K. Sezgin, H. Dağgez, D.P. Renders, and Y. Yakupoğullari. Microbial Pathogenesis, 2025. 200: 107287. PMID[39800168].
[PubMed]. TB_03_2025.

5. Nanoenabling MbtI Inhibitors for Next-generation Tuberculosis Therapy. Cazzaniga, G., M. Mori, A. Griego, E. Scarpa, G. Moschetti, S. Muzzioli, G. Stelitano, L.R. Chiarelli, M. Cocorullo, E. Casali, A. Porta, G. Zanoni, A. Tresoldi, E. Pini, L. Batalha Í, G. Battaglia, T. Tuccinardi, L. Rizzello, S. Villa, and F. Meneghetti. Journal of Medicinal Chemistry, 2025. 68(5): p. 5312-5332. PMID[40029993]. PMCID[PMC11912484].
[PubMed]. TB_03_2025.

6. Volatile Compounds of Hexane Extract from Pterodon pubescens Benth Seeds and Its Significant In Vitro Potential against Different Bacterial Strains. Dos Santos, J.G., C.C. Fernandes, N.B.S. Silva, G.G. Calefi, C.H.G. Martins, G.A. Volpini, A.E.M. Crotti, A.B. Ribeiro, T.R. Esperandim, D.C. Tavares, C. Batalini, and M.L.D. Miranda. Natural Product Research, 2025. 39(5): p. 1428-1433. PMID[38143320].
[PubMed]. TB_03_2025.

7. In Vitro Antibacterial and DPPH Radical Inhibitory Activities and In Silico Molecular Simulation of Compounds Isolated from the Leaves of Olinia rochetiana. Duguma, T., Y. Melaku, D. Rentsch, M. Hunsen, T.B. Demissie, and N. Kgakatsi. ACS Omega, 2025. 10(9): p. 9547-9562. PMID[40092772]. PMCID[PMC11904691].
[PubMed]. TB_03_2025.

8. Novel Quinoline Derivatives: Synthesis, Spectroscopic Characterization, Crystal Structure, DFT Calculations, Hirshfeld Surface Analysis, Anti-tuberculosis Activities and ADMET Analysis. Geng, Y.D., S. Wang, Y.X. Zhang, Y. Liu, H.L. Tang, X.L. Li, and Y.X. Gong. Journal of Molecular Structure, 2025. 1332: 141751. ISI[001428568200001].
[WOS]. TB_03_2025.

9. Triple Antimicrobial Combinations with Potent Synergistic Activity against M. Abscessus. Huang, Y.Q., L. Chiaraviglio, I. Bode-Sojobi, and J.E. Kirby. Antimicrobial Agents and Chemotherapy, 2025. 69(4): p. e018284. PMID[40084880]. PMCID[PMC11963555].
[PubMed]. TB_03_2025.

10. Novel Quinoline-imidazole Derivatives as Inhibitors of Mycobacterium tuberculosis: An Integrated Approach Combining Molecular Dynamics and In-vitro Studies. Khebude, N., S.G. Alegaon, S.D. Ranade, D. Sriram, R.S. Kavalapure, M. Singh, S. Gharge, and S.S. Jalalpure. Molecular Simulation, 2025. ISI[001445409400001].
[WOS]. TB_03_2025.

11. Exploration of Quinoxaline Triazoles as Antimycobacterial Agents: Design, Synthesis and Biological Evaluation. Kumar, B.V.S., M.K. Talamadla, A. Nandikolla, Y.M. Khetmalis, G. Shetye, S.G. Franzblau, S. Murugesan, and K. Sekhar. Bioorganic & Medicinal Chemistry Letters, 2025. 121: 130177. PMID[40058415].
[PubMed]. TB_03_2025.

12. Chroman-schiff Base Derivatives as Potential Anti-tubercular Agents: In Silico Studies, Synthesis, and Biological Evaluation. Mujeeb, S., K. Singh, M.K. Al-Zrkani, D. Al-Fahad, S.M. Hasan, M.A. Shouber, F. Ahmad, H.N. Hameed, D. Iqbal, and M. Kamal. Bioorganic Chemistry, 2025. 157: 108249. PMID[39965447].
[PubMed]. TB_03_2025.

13. Design, Synthesis, and In Vitro and In Silico Biological Exploration of Novel Pyridine-embedded 1,3,4-oxadiazole Hybrids as Potential Antimicrobial Agents. Shivakumara, K.N., S.M. Basavarajaiah, G.Y. Nagesh, K. Prashantha, M. Yogesh, N.R. Abhishek, and H.N. Odesha. Journal of Chemistry, 2025. 2025(1): 4427650. ISI[001434816300001].
[WOS]. TB_03_2025.

14. Host-mediated Antimicrobial Effects and NLRP3 Inflammasome Modulation by Caulerpin and Its Derivatives in Macrophage Models of Mycobacterial Infections. Sidrônio, M.G.S., M.E.G. Freitas, D.W.A. Magalhães, D.C.M. Carvalho, V.A.B. Gonçalves, A. Oliveira, G.C. Paulino, G.C. Borges, R.L. Ribeiro, N.F. Sousa, M.T. Scotti, D.A.M. Araújo, F.J.B. Mendonça-Junior, K.R.L. Freire, S. Rodrigues-Mascarenhas, B.V.O. Santos, and V.S. Rodrigues-Junior. Microorganisms, 2025. 13(3). PMID[40142455]. PMCID[PMC11944515].
[PubMed]. TB_03_2025.

15. Synthesis, Spectral Characterization, Antimicrobial Activity, DFT Calculations, Molecular Docking and ADME Studies of Novel Schiff Base Co(II), Ni(II), Cu(II) and Zn(II) Complexes Derived from 4-nitro-ortho-phenylenediamine. Sindhu, I., A. Singh, Y. Deswal, and N.M. Gupta. Chemistry & Biodiversity, 2025. 22(3): e202402619. PMID[39590220].
[PubMed]. TB_03_2025.

16. In Vitro Activity of Omadacycline against Geographically Diverse Rapidly Growing Nontuberculous Mycobacteria (NTM) Clinical Isolates. Terschlüsen, E., A. Aono, D.M. Anastasiou, A.W. Serio, S. Mitarai, and J. van Ingen. Diagnostic Microbiology and Infectious Disease, 2025. 111(3): 116663. PMID[39808861].
[PubMed]. TB_03_2025.

17. Synthesis, Computational, and Photophysical Probing Interactions of Novel Isatin-incorporated Thiazolyl-coumarins as Potent Antitubercular Agents. Vinay, K.K., Y.D. Bodke, N. Shivakumar, and U. Dalimba. Chemistryselect, 2025. 10(10): e202404193. ISI[001438945600001].
[WOS]. TB_03_2025.

18. Discovery of 1,3-disubstituted Pyrazole Derivatives as Mycobacterium tuberculosis Inhibitors. Wan, G., C. Gao, X. Zhang, H. Qiu, Q. Tang, J. Zeng, and L. Yu. Bioorganic & Medicinal Chemistry Letters, 2025. 121: 130156. PMID[40024479].
[PubMed]. TB_03_2025.

19. Isolation and Investigation of Anti-tubercular Ilicic Acid from Sphaeranthus indicus against Mycobacterium tuberculosis H(37)Rv and MDR Strains. Yagoo, A., M.C.J. Milton, J. Vilvest, A.A. Ahino Jessie, and K. Balakrishna. Regulatory Toxicology and Pharmacology, 2025. 158: 105800. PMID[40043881].
[PubMed]. TB_03_2025.

20. Corrigendum to "Structure-based Development of N-arylindole Derivatives as PKS13 Inhibitors against Mycobacterium tuberculosis" [Europ. J. Med. Chem. 283 (2025) 117148]. Zhang, X., S. Lun, Y.X. Li, W. Zhang, R.Y. Zhou, T. Liu, F. Yang, J. Tang, W.R. Bishai, and L.F. Yu. European Journal of Medicinal Chemistry, 2025. 285: 117239. PMID[39779391].
[PubMed]. TB_03_2025.

21. Structure-based Development of 3,4-fused Tricyclic Benzofuran Derivatives as Polyketide Synthase 13 Inhibitors with Negligible HERG Inhibition. Zhou, Y.X., S. Lun, W. Zhang, F.J. Tie, Y.P. Cai, F. Yang, J. Tang, W.R. Bishai, and L.F. Yu. Journal of Medicinal Chemistry, 2025. 68(6): p. 6312-6327. PMID[40045825].
[PubMed]. TB_03_2025.

Patent Citations

This month, no relevant Mycobacterium patents were identified.